The PREP-S model had been developed using a UK population, and validated using data from similar multinational settings. It was noted that further validation of PREP-S was unlikely to be conducted, because of the cost of conducting these studies. The committee therefore agreed that both models could be considered as options, in addition to a full clinical assessment, to help guide decisions relating to interventions and place of care. The tools predict adverse outcomes in women, but are not designed to predict outcomes for babies. The committee agreed it was important to highlight this. How the recommendations might affect practice The use of a full clinical assessment and validated models to predict risk may improve consistency in current practice with regard to admission to hospital for women with pre- eclampsia. Some centres offer admission to all women with pre-eclampsia, whereas others only offer it to a small proportion of women. The guidance might increase the number of women who are admitted to hospital in some centres if admission is not currently routine, but might decrease admission in other centres, thus standardising practice. Full details of the evidence and the committee's discussion are in evidence review C: prediction of complications in pre-eclampsia. Return to recommendations Monitoring and treatment of pre-eclampsia and timing of birth Why the committee made the recommendations The committee updated the table from the previous guideline on the management of pregnancy with pre-eclampsia. There was limited evidence on the best place of treatment for women with pre-eclampsia. 